<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762824</url>
  </required_header>
  <id_info>
    <org_study_id>IPS-BOOSTER</org_study_id>
    <nct_id>NCT03762824</nct_id>
  </id_info>
  <brief_title>Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease</brief_title>
  <acronym>IPS-BOOSTER</acronym>
  <official_title>Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this project is to study the influence of modern anti-inflammatory
      treatments in established inflammatory rheumatic diseases (IRD) on antibody response elicited
      by pneumococcal vaccination using 13-valent conjugate vaccine in combined schedules with
      23-valent polysaccharide vaccine. In addition, the aim is to study the clinical aspects of
      vaccination regarding: tolerability in immunosuppressed patients with IRD, impact on existing
      rheumatic disease, possible association with onset of new autoimmune diseases, long-term
      immunity following pneumococcal vaccination and efficacy in preventing invasive pneumococcal
      disease. Results from this study are expected to bridge the existing knowledge gap and
      contribute to body of evidence needed for recommendations and implementation of vaccination
      program in IRD patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 14, 2016</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 3, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-fold rise in pneumococcal serotype-specific antibody concentration</measure>
    <time_frame>8 weeks after pneumococcal conjugate vaccine and 4-6 weeks after polysaccharide vaccination</time_frame>
    <description>Pneumococcal serotype-specific antibody concentration (12-valent)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional antibody response</measure>
    <time_frame>8 weeks after pneumococcal conjugate vaccine and 4-6 weeks after polysaccharide vaccination</time_frame>
    <description>Opsonophagocytosis activity assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term serotype-specific immunity to pneumococcal disease</measure>
    <time_frame>3 years after vaccination</time_frame>
    <description>Pneumococcal serotype-specific antibody concentration</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Systemic Lupus</condition>
  <condition>Sjögren Syndrome</condition>
  <condition>Systemic Vasculitis</condition>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>PCV13+PPV23 vaccinated patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with different inflammatory rheumatic diseases are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV13+PPV23 vaccinated controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV23-booster to previous PCV-vaccinated patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with different inflammatory rheumatic disease previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV13 to previous PPV23-vaccinated patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with different inflammatory rheumatic disease previously immunized with one dose PPV23 within another study (see VACCIMIL), are immunized with one dose PCV13 0.5 ml i.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV23-booster to previous PCV-vaccinated controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Pneumococcal conjugate vaccination during antirheumatic treatment</description>
    <arm_group_label>PCV13 to previous PPV23-vaccinated patients</arm_group_label>
    <arm_group_label>PCV13+PPV23 vaccinated controls</arm_group_label>
    <arm_group_label>PCV13+PPV23 vaccinated patients</arm_group_label>
    <other_name>Prevenar 13</other_name>
    <other_name>PCV13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent pneumococcal polysaccharide vaccine</intervention_name>
    <description>Pneumococcal polysaccharide vaccination during antirheumatic treatment</description>
    <arm_group_label>PCV13+PPV23 vaccinated controls</arm_group_label>
    <arm_group_label>PCV13+PPV23 vaccinated patients</arm_group_label>
    <arm_group_label>PPV23-booster to previous PCV-vaccinated controls</arm_group_label>
    <arm_group_label>PPV23-booster to previous PCV-vaccinated patients</arm_group_label>
    <other_name>Pneumovax</other_name>
    <other_name>PPV23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with IRD receiving active anti-rheumatic treatments with DMARDs or
             biological remedies are offered to participate in the study. The protocol permits
             stratification for prednisolone usage.

        Exclusion Criteria:

          -  known allergy/intolerance of pneumococcal vaccine

          -  pregnancy

          -  active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jehns Martineus, MD</last_name>
    <role>Study Director</role>
    <affiliation>Skåne Universitets sjukhus, dept of rheumatology</affiliation>
  </overall_official>
  <reference>
    <citation>Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 Sep;46(9):2287-93.</citation>
    <PMID>12355475</PMID>
  </reference>
  <reference>
    <citation>Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):106-11. Epub 2005 Nov 15.</citation>
    <PMID>16287919</PMID>
  </reference>
  <reference>
    <citation>Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011 Dec;63(12):3723-32. doi: 10.1002/art.30580.</citation>
    <PMID>21834061</PMID>
  </reference>
  <reference>
    <citation>Nived P, Nagel J, Saxne T, Geborek P, Jönsson G, Skattum L, Kapetanovic MC. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 2017 Jun 22;35(29):3639-3646. doi: 10.1016/j.vaccine.2017.05.044. Epub 2017 May 25.</citation>
    <PMID>28552512</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816-9.</citation>
    <PMID>23051612</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal Conjugate Vaccine</keyword>
  <keyword>Pneumococcal Disease</keyword>
  <keyword>Immune Response</keyword>
  <keyword>Inflammatory Rheumatic Disease</keyword>
  <keyword>Pneumococcal Polysaccharide Vaccine</keyword>
  <keyword>Immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>If requested we will consider sharing unidentified individual patient data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

